Navigation Links
VIVUS to Present at the Deutsche Bank BioFEST Conference
Date:12/1/2011

s. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  p
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results
2. VIVUS to Present at the BioCentury NewsMakers Conference
3. VIVUS to Participate in Three Investor Conferences in September
4. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
5. VIVUS Reports First Quarter 2011 Financial Results
6. VIVUS to Present at Four Upcoming Investor Conferences in May
7. VIVUS to Present at the 10th Annual Needham Healthcare Conference
8. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
9. VIVUS to Present at Four Upcoming Investor Conferences
10. VIVUS to Present at Two Upcoming Investor Conferences
11. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
(Date:5/1/2015)... Investor-Edge has initiated coverage ... GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ), ... research report on Genetic Technologies can be accessed ... 2015, the NASDAQ Composite ended at 4,941.42, down ...
(Date:4/30/2015)... 01, 2015 Spirax Sarco, the leader ... proud to announce that for the first time in ... winner of a Queen’s Award for Innovation – the ... and manufacture of a unique flowmeter. , The Spirax ... to traditional steam flow measurement. The device provides ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... ... attracts investors, COLUMBUS, Ohio, Aug. ... for venture capital investments in biotech innovation and,business growth, according ... markets the state for capital,investment. The report, released by BioEnterprise, ...
... Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today ... a challenge of the patent listed by,Warner Chilcott ... (norethindrone and ethinyl estradiol) chewable oral contraceptive. The,Company ... an Abbreviated New Drug,Application (ANDA) containing a paragraph ...
... Keck Graduate Institute,(KGI) today announced the election of ... M. Burzik, chief executive officer of Kinetic Concepts,Inc.; ... at,Gilead Sciences; and Peter Barton Hutt, senior counsel ... of leaders in business, industry and education who,have ...
Cached Biology Technology:Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3KGI Elects Three New Members to Board of Trustees 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... 2010): Today, the Association for Molecular Pathology (AMP) submitted written ... the National Institutes of Health (NIH) for its Genetic Test ... to formulate a comprehensive response to the RFI. "With ... setting, AMP is able to inform the NIH on the ...
... While pundits write obituaries for the 2010 climate bill, ... the world. We are losing species and ecosystems are unraveling ... We need new tools and strategies to deal with these ... to announce the launch of their new Climate Adaptation Knowledge ...
... PHILADELPHIAIn 1824, three years before he began to publish his ... Audubon (1785-1851), the eminent artist of American birds and animals, ... the design for a New Jersey bank note. Although the ... in two separate diary entries, no one has ever been ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2CAKE offers way forward for climate change adaptation 2Discovered: Audubon's first engraving of a bird 2
... System brings together two mature, well-understood ... capture surfaces. This combination produces a ... the detection of molecular binding events ... , Protein-specific capture molecules are immobilized ...
... globigii 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: ... or phenol treatment followed by ethanol precipitation. ... KCl, 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, ... dry ice. Store at -20C. Unit Definition: ...
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
Biology Products: